github link
Accession IconGSE18864

Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients

Organism Icon Homo sapiens
Sample Icon 84 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description
Evidence suggests that BRCA1 mutation associated tumors have increased sensitivity to DNA damaging agents like cisplatin. Sporadic triple negative breast cancers (TNBC) have many phenotypic similarities to BRCA1 tumors and may have a similar sensitivity to cisplatin. We tested the efficacy of cisplatin monotherapy in 28 TNBC patients in a single arm neoadjuvant trial with outcome measured by pathologic treatment response quantified using the Miller-Payne scale.
PubMed ID
Total Samples
84
Submitter’s Institution

Samples

Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Age
Disease stage
Processing Information
Additional Metadata
No rows found
Loading...